TG THERAPEUTICS INC (TGTX)
US88322Q1085 - Common Stock
TGTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. TGTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TGTX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
TGTX had negative earnings in the past year.
In the past year TGTX has reported a negative cash flow from operations.
In the past 5 years TGTX reported 4 times negative net income.
In the past 5 years TGTX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -2.45%, TGTX belongs to the top of the industry, outperforming 90.57% of the companies in the same industry.
TGTX's Return On Equity of -7.48% is amongst the best of the industry. TGTX outperforms 91.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.45% | ||
| ROE | -7.48% | ||
| ROIC | N/A |
ROA(3y)-63.44%
ROA(5y)-68.2%
ROE(3y)-159.11%
ROE(5y)-195.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of TGTX (88.32%) is better than 91.28% of its industry peers.
The Profit Margin and Operating Margin are not available for TGTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TGTX has more shares outstanding
TGTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TGTX has an improved debt to assets ratio.
2.2 Solvency
TGTX has an Altman-Z score of 5.29. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
TGTX's Altman-Z score of 5.29 is amongst the best of the industry. TGTX outperforms 80.96% of its industry peers.
A Debt/Equity ratio of 1.27 is on the high side and indicates that TGTX has dependencies on debt financing.
TGTX has a Debt to Equity ratio of 1.27. This is in the lower half of the industry: TGTX underperforms 79.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.29 |
ROIC/WACCN/A
WACC10.96%
2.3 Liquidity
A Current Ratio of 4.59 indicates that TGTX has no problem at all paying its short term obligations.
TGTX has a Current ratio (4.59) which is comparable to the rest of the industry.
TGTX has a Quick Ratio of 3.91. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a Quick ratio (3.91) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.59 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.71% over the past year.
TGTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.51%.
TGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 335.01% yearly.
EPS 1Y (TTM)60.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-97.26%
Revenue 1Y (TTM)39.51%
Revenue growth 3Y1059.22%
Revenue growth 5Y335.01%
Sales Q2Q%-49.41%
3.2 Future
The Earnings Per Share is expected to grow by 231.25% on average over the next years. This is a very strong growth
Based on estimates for the next years, TGTX will show a very strong growth in Revenue. The Revenue will grow by 42.99% on average per year.
EPS Next Y1366.25%
EPS Next 2Y891.48%
EPS Next 3Y486.05%
EPS Next 5Y231.25%
Revenue Next Year42.85%
Revenue Next 2Y53.02%
Revenue Next 3Y47.8%
Revenue Next 5Y42.99%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
TGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 32.72 indicates a quite expensive valuation of TGTX.
Based on the Price/Forward Earnings ratio, TGTX is valued cheaply inside the industry as 93.24% of the companies are valued more expensively.
TGTX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.99, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 32.72 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TGTX's earnings are expected to grow with 486.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y891.48%
EPS Next 3Y486.05%
5. Dividend
5.1 Amount
No dividends for TGTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TG THERAPEUTICS INC
NASDAQ:TGTX (12/24/2024, 7:41:00 PM)
After market: 32.8058 +0.65 (+2.01%)32.16
-0.1 (-0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners61.18%
Inst Owner Change9.27%
Ins Owners9.59%
Ins Owner Change-0.24%
Market Cap5.01B
Analysts80
Price Target39.44 (22.64%)
Short Float %20.64%
Short Ratio9.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)76.13%
Min EPS beat(2)-33.53%
Max EPS beat(2)185.79%
EPS beat(4)2
Avg EPS beat(4)16.52%
Min EPS beat(4)-92.18%
Max EPS beat(4)185.79%
EPS beat(8)4
Avg EPS beat(8)66.09%
EPS beat(12)7
Avg EPS beat(12)50.32%
EPS beat(16)7
Avg EPS beat(16)32.35%
Revenue beat(2)2
Avg Revenue beat(2)4.98%
Min Revenue beat(2)0.65%
Max Revenue beat(2)9.31%
Revenue beat(4)4
Avg Revenue beat(4)7.88%
Min Revenue beat(4)0.65%
Max Revenue beat(4)13.96%
Revenue beat(8)6
Avg Revenue beat(8)37.84%
Revenue beat(12)8
Avg Revenue beat(12)33.32%
Revenue beat(16)9
Avg Revenue beat(16)14.34%
PT rev (1m)12.78%
PT rev (3m)12.78%
EPS NQ rev (1m)-2.79%
EPS NQ rev (3m)1521.01%
EPS NY rev (1m)-2.73%
EPS NY rev (3m)-2.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)27.49%
Revenue NY rev (1m)0.26%
Revenue NY rev (3m)0.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 32.72 | ||
| P/S | 18.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 26.05 | ||
| P/tB | 26.05 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.11
EYN/A
EPS(NY)0.98
Fwd EY3.06%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS1.7
BVpS1.23
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.45% | ||
| ROE | -7.48% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.32% | ||
| FCFM | N/A |
ROA(3y)-63.44%
ROA(5y)-68.2%
ROE(3y)-159.11%
ROE(5y)-195.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 24% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.59 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | 5.29 |
F-Score2
WACC10.96%
ROIC/WACCN/A
Cap/Depr(3y)48.73%
Cap/Depr(5y)100.24%
Cap/Sales(3y)2.11%
Cap/Sales(5y)66.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-97.26%
EPS Next Y1366.25%
EPS Next 2Y891.48%
EPS Next 3Y486.05%
EPS Next 5Y231.25%
Revenue 1Y (TTM)39.51%
Revenue growth 3Y1059.22%
Revenue growth 5Y335.01%
Sales Q2Q%-49.41%
Revenue Next Year42.85%
Revenue Next 2Y53.02%
Revenue Next 3Y47.8%
Revenue Next 5Y42.99%
EBIT growth 1Y97.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year227.32%
EBIT Next 3Y111.14%
EBIT Next 5YN/A
FCF growth 1Y88.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.26%
OCF growth 3YN/A
OCF growth 5YN/A